Worldwide CAR-T cell therapies market is gaining significant growth in North America

 

Worldwide CAR-T cell therapies market is gaining significant growth in North America

Market Overview:

CAR-T cell therapies is advanced cancer therapy and is highly preferred over surgery, chemotherapy, and radiation. These target cancer cells and strengthen the patient’s immune system against the tumor.

The global Car TCell therapy market is estimated to be valued at US$ 1,085.0 million in 2021 and is expected to exhibit a CAGR of 24.5% during the forecast period (2021-2028).

Key Drivers

According to the World Health Organization, cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. There is a high prevalence of cancer around the globe. Growing number of patients showing failure response to the alternative cancer treatments is a prime factor driving growth of the CAR T cell therapy market.

Increasing development of development of new and effective therapy options to cure cancer is again driving growth of the market growth. For instance, in July 2020, Kite, a Gilead Company announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to Tecartus™ (brexucabtagene autoleucel, formerly KTE-X19), the first and only approved chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).

Comments

Popular posts from this blog

Growing prevalence of cancer to augment growth of companion diagnostic market

The Global 3D Printing For Medical Sector Market Growing to the Increasing Prevalence of Healthcare